Millie
your market intelligence analyst
Search Results
362 results
Your search is now limited to «Cancer Drugs» expert search.
ClinicalTrials.gov 08/05/2020 07:19
Conditions : Constitutional Mismatch Repair Deficiency Syndrome; Hematopoietic and Lymphoid Cell Neoplasm; Lynch Syndrome; Recurrent Lymphoma; Recurrent Malignant Solid Neoplasm; Recurrent Neuroblastoma; Recurrent Primary Central Nervous System Neoplasm; Refractory Lymphoma; Refractory Malignant Solid Neoplasm; Refractory Neuroblastoma; Refractory Primary Central Nervous System Neoplasm; Xeroderma Pigmentosum Interventions : Procedure: Biospecimen Collection; Biological: Ipilimumab; Biological: Nivolumab Sponsor : National Cancer Institute (NCI) Not yet recruiting.
More from ClinicalTrials.gov:
Medical Xpress - Cancer News 08/04/2020 14:11
Scientists accelerate progress in preventing drug resistance in lung and pancreas cancers.
More from Medical Xpress - Cancer News:
PharmiWeb.com 08/04/2020 04:53
Rafael Pharmaceuticals intends to apply for orphan drug designation for CPI-613 for MYC amplified lymphoma/Burkitt lymphoma and T-cell lymphoma in the near future.
More from PharmiWeb.com:
The NSD2 p.E1099K (EK) mutation is observed in 10% of acute lymphoblastic leukemia (ALL) samples with enrichment at relapse indicating a role in clonal evolution and drug resistance. To discover mechanisms that mediate clonal expansion, we engineered B-precursor ALL (B-ALL) cell lines (Reh, 697) to overexpress wildtype (WT) and EK NSD2, but observed no differences in proliferation, clonal growth, or chemosensitivity. To address whether NSD2 EK acts collaboratively with other pathways, we used short hairpin RNAs to knockdown expression of NSD2 in B-ALL cell lines heterozygous for NSD2 EK (RS4;11, RCH-ACV, SEM). Knockdown resulted in decreased proliferation in all lines, decreased clonal growth in RCH-ACV, and increased sensitivity to cytotox.
More from Molecular Cancer Research - Recent Issues (abstracts):
GlobeNewswire 08/03/2020 09:00
PharmaCyte’s therapy for cancer involves encapsulating genetically engineered human cells that convert an inactive chemotherapy drug into its active or “cancer-killing” form.
More from GlobeNewswire:
Business Wire 08/03/2020 08:00
Clinical trial data have shown that SM-88 has demonstrated encouraging tumor responses across 15 different cancers, including pancreatic, lung, breast, prostate and sarcoma cancers with minimal serious grade 3 or higher adverse events.
More from Business Wire:
This rapid, efficient, and noninvasive method for generating cultures of bladder cancer cells can be used potentially for high-throughput drug screening, predicting patient clinical responses, and monitoring tumor initiation and recurrence.
More from Clinical Cancer Research - Recent Issues (abstracts):
Medindia.com 07/31/2020 05:27
Ibrutinib drug has the potential to decrease rates of respiratory failure and death in COVID-19-infected patients.
More from Medindia.com:
Pharmafile 07/31/2020 05:19
NICE has revealed that a combination of Merck KGaA’s Bavencio (avelumab) and Pfizer’s Inlyta (axitinib) will be made available as a first-line treatment for advanced renal cell carcinoma via the Cancer Drugs Fund.
More from Pharmafile:
News-Medical.net 07/30/2020 10:32
This suggests the steroid-production pathway could be a real contender in the search for drug targets for designing cancer immunotherapies, to help treat cancer patients.
More from News-Medical.net:
ETHealthWorld (India) 07/30/2020 04:30
Piramal Pharma provides integrated drug development model to Bolt's cancer medicine, Health News, ET HealthWorld.
More from ETHealthWorld (India):
STAT 07/29/2020 07:00
The pharmaceutical giant GlaxoSmithKline is starting human trials of the first medicine, a cancer drug, that has emerged from its two-year-old collaboration with consumer genetics firm 23andMe.
More from STAT:
Nano-sized drug delivery systems are used for the treatment of cancers.
More from International Journal of COPD:
This guidance describes FDA’s recommendations to investigational new drug sponsors for setting endotoxin limits during the development of investigational drugs intended for use in combination with other approved drugs or for the codevelopment of two or more investigational drugs.
More from U.S. Food & Drug Administration - FDA - What's New: Drugs (FDA):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications